NHS Dudley Health Economy Medicines Formulary
Home > 6 Endocrine system > 6.1 Drugs used in diabetes > 6.1.2 Antidiabetic drugs > Dapagliflozin in triple therapy for treating type 2 diabetes - NICE TAG TA418

Dapagliflozin in triple therapy for treating type 2 diabetes - NICE TAG TA418

1.1 Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.

1.2 This guidance is not intended to affect the position of patients whose treatment with dapagliflozin in other triple therapy regimens was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta418

Site by Devopa
© Copyright 2020 NHS. All rights reserved.